Literature DB >> 23475798

Role of tricuspid valve repair for moderate tricuspid regurgitation during minimally invasive mitral valve surgery.

Bettina Pfannmueller1, Alexander Verevkin, Michael Andrew Borger, Meinhard Mende, Piroze Davierwala, Jens Garbade, Friedrich Wilhelm Mohr, Martin Misfeld.   

Abstract

BACKGROUND: The aim of this study was to investigate the impact of short- and mid-term survival of tricuspid valve (TV) repair versus conservative therapy in patients with preoperative moderate functional tricuspid regurgitation (TR) undergoing minimally invasive mitral valve (MV) surgery.
METHODS: Between January 2002 and December 2009, a total of 430 patients with pure mitral regurgitation and concomitant moderate TR underwent minimally invasive MV surgery for mitral regurgitation at the Leipzig Heart Center without (n = 336; group A) and with (n = 94; group B) TV surgery. Mean age was 66.7 ± 10.3 years, mean LVEF was 58.0 ± 13.8%, and 206 patients (47.9%) were male. Average logEuroSCORE was 12.4 ± 11.4%. Follow-up was on average 4.6 ± 2.4 years and 97% completed.
RESULTS: Predischarge echocardiography showed no or mild TR in 51.1% of patients in group A versus 84.2% of patients in group B (p < 0.01). Overall 30-day mortality was 2.8% with no differences between both groups. Five-year survival was 82.9 ± 4.1% for patients with TV repair versus 85.0 ± 2.2% for patients without TV repair (p = 0.1) and it was 85.7 ± 3.3% in patients with moderate and more postoperative TR versus 90.1 ± 2.5% in patients with less than moderate postoperative TR (p = 0.08). Five-year freedom from TV-related reoperation was 98.8 ± 0.7% for patients in group A versus 98.9 ± 0.1% for patients in group B (p = 0.8).
CONCLUSIONS: Patients undergoing MV surgery with moderate functional TR do not experience increased perioperative complication rates when a concomitant TV repair is performed. Our observations, combined with those of other groups, support current recommendations to perform concomitant TV repair in such patients, particularly if tricuspid annular dilation is present. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2013        PMID: 23475798     DOI: 10.1055/s-0033-1333844

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  6 in total

1.  Current transcatheter devices to treat functional tricuspid regurgitation with discussion of issues relevant to clinical trial design.

Authors:  Rebecca T Hahn
Journal:  Ann Cardiothorac Surg       Date:  2017-05

2.  Concomitant tricuspid valve repair in patients with minimally invasive mitral valve surgery.

Authors:  Bettina Pfannmüller; Piroze Davierwala; Gregor Hirnle; Michael A Borger; Martin Misfeld; Jens Garbade; Joerg Seeburger; Friedrich W Mohr
Journal:  Ann Cardiothorac Surg       Date:  2013-11

3.  Tricuspid annulus: a three-dimensional deconstruction and reconstruction.

Authors:  Khurram Owais; Charles E Taylor; Luyang Jiang; Kamal R Khabbaz; Mario Montealegre-Gallegos; Robina Matyal; Joseph H Gorman; Robert C Gorman; Feroze Mahmood
Journal:  Ann Thorac Surg       Date:  2014-09-22       Impact factor: 4.330

4.  Hospital outcome of concomitant tricuspid annuloplasty during totally endoscopic mitral valve surgery: a propensity matched study.

Authors:  Ling-Chen Huang; Qi-Chen Xu; Dao-Zhong Chen; Xiao-Fu Dai; Liang-Wan Chen
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

5.  Transcatheter tricuspid interventions: time to re-think guidelines?

Authors:  Ana Paula Tagliari; Maurizio Taramasso
Journal:  Aging (Albany NY)       Date:  2020-01-27       Impact factor: 5.682

6.  Long-term outcomes of concomitant tricuspid valve repair in patients undergoing mitral valve surgery.

Authors:  Ayse Cetinkaya; Natalia Ganchewa; Stefan Hein; Karin Bramlage; Peter Bramlage; Markus Schönburg; Manfred Richter
Journal:  J Cardiothorac Surg       Date:  2020-08-04       Impact factor: 1.637

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.